Skip to main content
SpringerLink
Log in

Epidemiology and endocrinology of benign breast disease

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Adams JB, Wong MSF: Paraendocrine behaviour of human breast carcinoma: In vitro transformation of steroids to physiologically active hormones. J Endocrinol 41: 41–52, 1968

    Google Scholar 

  2. Agrimonti F, Cavallo R, Friaria R, Violino PL, Borretta G, Angeli A: Immunoglobulin levels in breast cyst fluid: apparent connection with intracystic transcortin (CBG) binding activity. Boll Ist Sieroter (Milan) 61:45–50, 1982

    Google Scholar 

  3. Allegra JC, Lippman ME, Green L, Barlock A, Simon R, Thompson EB, Huff KK, Griffin W: Estrogen receptor values in patients with benign breast disease. Cancer 44:228–231, 1979

    PubMed  Google Scholar 

  4. Angeli A, Bocuzzi G, Agrimonti F, Brignardello E, Barbadoro E, Dogliotti L: Correlation between levels of dehydroepiandrosterone sulphate and prolactin in human breast cyst fluid. Tumori 68:393–396, 1982

    PubMed  Google Scholar 

  5. Atkins HJB: The painful nodular breast: A plea for the term fibro-adenosis. Lancet i:253–255, 1947

    Google Scholar 

  6. Bacigalupo G: Uber die Rolle der Oestrogene bei Mastopathie und Brustkrebs. Deutsch Gesund 17:180–187, 1962

    Google Scholar 

  7. Bacigalupo g, Schubert K: Untersuchungen uber die Oestrogenausscheidung im Urin bei Mastopathie. Klin Wochenschrift 38: 804–805, 1960

    Google Scholar 

  8. Bacigalupo G, Schubert K: Some aspects of oestrogen metabolism in cases of human mammary neoplasias. Europ J Cancer 2:75–83, 1966

    Google Scholar 

  9. Bagli NP, Shah PN, Mistry SS: The estriol quotient in fibrocystic disease, a high-risk group for breast cancer. Indian J Cancer 17:201–204, 1980

    PubMed  Google Scholar 

  10. Bahu RM, Mangkornkanok-Mark M, Albertson D, Fors E, Molteni A, Battifora H: Detection of alpha-lactalbumin in breast lesions and relationship to estrogen receptors and serum prolactin. Cancer 46:1775–1780, 1980

    PubMed  Google Scholar 

  11. Balbi C, Candido R, D'Ajello M: Tassi ematici dell'estradiolo e del'progesterone nelle mastopatie benigne. Arch Obst Ginecol 83:93–97, 1978

    Google Scholar 

  12. Bertini BB, Ber A: The ethnologic and endocrinological aspects of breast cancer and cystic mastopathy in Israel. Cancer 17: 438–449, 1964

    PubMed  Google Scholar 

  13. Billroth T: Die Krankheiten der weiblichen Brustdrussen. Deutsche Chirurgie 41:1–55, 1880

    Google Scholar 

  14. Bischoff J, Rebhan EM, Prestele H, Becker H: Serumprolaktin und Anamnesevergleich bei Mammazysten und zystischer Mastopathie. Geburtsh Frauenheilk 40:65–71, 1980

    PubMed  Google Scholar 

  15. Bjorklund B, Bjorklund V: Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: Presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy Appl Immunol 10:153–161, 1957

    PubMed  Google Scholar 

  16. Black MM, Barclay TH, Cutler ST, Hankey BF, Asire AJ: Association of atypical characteristics of benign breast lesions with subsequent risk of breast cancer. Cancer 29:388–343, 1972

    Google Scholar 

  17. Bloodgood JC: The pathology of chronic cystic mastitis of the female breast with special consideration of the bluedomed cyst. Arch Surg 3:445–542, 1921

    Google Scholar 

  18. Boot LM: Prolactin and mammary gland carcinogenesis. The problem of human prolactin. Int J Cancer 5:167–175, 1970

    PubMed  Google Scholar 

  19. Boston Collaborative Group: Oral contraceptives and venous thromboembolic disease, surgically-confirmed gallbladder disease and breast tumours. Lancet i:1399–1404, 1973

    Google Scholar 

  20. Boyns AR, Cole EN, Griffiths K, Roberts MM, Buchan R, Wilson RG, Forrest APM: Plasma prolactin in breast cancer. Europ J Cancer 9:99–102, 1973

    Google Scholar 

  21. Bradlow HL, Rosenfeld RS, Kream J, Fleisher M, O'Connor J, Schwartz MK: Steroid hormone accumulation in human breast cyst fluid. Cancer Res 41:105–107, 1981

    PubMed  Google Scholar 

  22. Bradlow HL, Schwartz MK, Fleisher M, Nisselbaum JS, Boyar R, O'Connor J, Fukushima DK: Accumulation of hormones in breast cyst fluid. J Clin Endocrinol Metab 49:778–782, 1979

    PubMed  Google Scholar 

  23. Brennan MJ, Bulbrook RD, Deshpande N, Wang DY, Hayward JL: Urinary and plasma androgens in benign breast disease. Lancet i:1076–1079, 1973

    Google Scholar 

  24. Brinton LA, Vessey MP, Flavel R, Yeates D: Risk factor for benign breast disease. Am J Epidemiol 113:203–214, 1981

    PubMed  Google Scholar 

  25. Brooks PG, Gart S, Heldfond AJ, Margolin ML, Allen AS: Measuring the effect of caffeine restriction on fibrocystic breast disease. The role of graphic stress telethermometry as an objective monitor of disease. J Reprod Med 26:279–282, 1981

    PubMed  Google Scholar 

  26. Brownsey B, Cameron EHD, Griffiths K, Gleave EN, Forrest APM, Campbell H: Plasma dehydroepiandrosterone sulphate levels in patients with benign and malignant breast disease. Europ J Cancer 8:131–137, 1972

    Google Scholar 

  27. Bucher NLR, Geschickter CF: Corpus luteum studies: 2. Pregnandiol and estrogen output in the urine of patients with chronic cystic mastitis. J Clin Endocrinol Metab 1:58–64, 1941

    Google Scholar 

  28. Buhl-Jorgensen SF, Fischerman K, Johanses H, Petersen B: Cancer risk in intraductal papilloma and papillomatosis. Surg Gynecol Obstet 127:1307–1312, 1968

    PubMed  Google Scholar 

  29. Bulbrook RD, Wang DY: Prolactin: Aetiology of breast cancer and hormone dependence in man. Revs Endocrine-Related Cancer 4:13–19, 1979

    Google Scholar 

  30. Cameron EHD, Griffiths K, Gleave EN, Stewart HJ, Forrest APM, Campbell H: Benign and malignant breast disease in South Wales: A study of urinary steroids. Brit Med J 4:768–771, 1970

    PubMed  Google Scholar 

  31. Campbell OJ: Relationship between cystic disease of the breast and carcinoma. Arch Surg 28:1001–1056, 1934

    Google Scholar 

  32. Cheatle GL, Cutler M: Tumours of the Breast. Arnold, London, 1931

    Google Scholar 

  33. Clagett OT, Plimpton NC, Root GT: Lesions of the breast. The relationship of benign lesions to carcinoma. Surgery 15:414–419, 1944

    Google Scholar 

  34. Cole EN, Sellwood RA, England PC, Griffiths K: Serum prolactin concentrations in benign breast disease throughout the menstrual cycle. Europ J Cancer 13:597–603, 1977

    Google Scholar 

  35. Cole P, Elwood JM, Kaplan SD: Incidence rates and risk factors of benign breast neoplasms. Am J Epidemiol 108:112–120, 1978

    PubMed  Google Scholar 

  36. Coombs LJ, Lilienfeld AM, Bross IDJ, Burnett W: A prospective study of the relationship between benign breast disease and breast carcinoma. Prev Med 8:40–52, 1979

    PubMed  Google Scholar 

  37. Cooper AP: The anatomy and diseases of the breast. 1845

  38. Cutler M: The cause of ‘painfull breasts’ and treatment by means of ovarian residue. J Am Med Assoc 96:1201–1205, 1931

    Google Scholar 

  39. Davis HH, Simons MA, Davis TB: Cystic disease of the breast: relationship to carcinoma. Cancer 17:957–978, 1964

    PubMed  Google Scholar 

  40. DeBoever J, Vanderkerckhove D: Benign breast disease: Steroid concentrations. J Steroid Biochem 17:cxiii, 1982

    Google Scholar 

  41. DeSanso G, Bracco G, Tanferna M, Graffino W, Panazzolo A: Ruolo dei tumori benigni e delle displasie mammarie nella cancerogenesi in relazione alla attivitia degli enzimi lisosomiali a-arilsolfatasi e b-glucuronidasi. Minerva Ginecol 33:185–196, 1981

    PubMed  Google Scholar 

  42. Delbet P: Maladie cystique de la mammelle. Bull Soc d'Anat de Paris 68:2, 1893

    Google Scholar 

  43. Devitt JE: Fibrocystic disease of the breast is not premalignant. Surg Gynecol Obstet 134:803–806, 1972

    PubMed  Google Scholar 

  44. Devitt JE: Breast cancer and preceding benign breast diseases. A chance association. Lancet i:793–795, 1976

    Google Scholar 

  45. Dilley WG, Leight GS, Silva JS, Ammirata S, Haagensen DE, Wells SA: Androgen stimulation of gross cystic disease fluid protein and carcinoembryonic antigen in patients with metastatic breast carcinoma. J Nat Cancer Inst 70:69–74, 1983

    PubMed  Google Scholar 

  46. Donnelly PK, Baker KW, Carney JA, O'Fallon WM: Benign breast lesions and subsequent breast carcinomas in Rochester Minnesota. Mayo Clin Proc 50:650–656, 1975

    PubMed  Google Scholar 

  47. Dowsett M, Gazet JC, Powles TJ, Easty GC, Neville AM: Benign breast lesions and osteolysis. Lancet i:970–971, 1976

    Google Scholar 

  48. England PC, Sellwood RA, Knyba RE, Irvine JDB: Serum androgen levels and the menstrual cycle in women with benign or malignant breast disease. Clin Oncol 7:213–219, 1981

    PubMed  Google Scholar 

  49. England PC, Skinner LG, Cottrell KM, Sellwood RA: Serum oestradiol-17β in women with benign and malignant breast disease. Brit J Cancer 30:571–576, 1974

    PubMed  Google Scholar 

  50. England PC, Skinner LG, Cottrell KM, Sellwood RA: Sex hormones in breast disease. Brit J Surg 62:806–809, 1975

    PubMed  Google Scholar 

  51. Ernster VA, Mason L, Goodson WH, Sickles EA, Sacks ST, Selvin S, Dupuy ME, Hawkinson J, Hunt TK: Effects of caffeine-free diet on benign breast disease. A randomized trial. Surgery 91:263–267, 1982

    PubMed  Google Scholar 

  52. Fasal E, Paffenbarger RS: Oral contraceptives as related to cancer and benign lesions of the breast. J Nat Cancer Inst 55:767–773, 1975

    PubMed  Google Scholar 

  53. Feherty P, Farrer-Brown G, Kellie AE: Oestradiol receptor in carcinoma and benign disease of the breast: An in vitro assay. Brit J Cancer 25:697–710, 1971

    PubMed  Google Scholar 

  54. Fleisher M, Breed C, Robbins G, Fracchia A, Urban J, Schwartz M: The elemental composition of human breast fluid. Clinical Chem 22:1213, 1976

    Google Scholar 

  55. Fleisher M, Oettegen HF, Breed CN, Robbins GF, Pinsky CM, Schwartz MK: CEA like material in fluid from benign cysts of the breast. Clin Chem 20:41–42, 1974

    PubMed  Google Scholar 

  56. Fleming NT, Armstrong BK, Sheiner HJ: The comparative epidemiology of benign breast lumps and breast cancer in Western Australia. Int J Cancer 30:147–152, 1982

    PubMed  Google Scholar 

  57. Foote FW, Stewart FW: Comparative studies of cancerous versus noncancerous breasts. Ann Surg 121:197–222, 1945

    Google Scholar 

  58. Fournier S, Kuttenn F, De Cicco F, Baudot N, Malet C, Mauvais-Jarvis P: Estradiol 17β-hydroxysteroid dehydrogenase activity in human breast fibroadenomas. J Clin Endocrinol Metab 55:428–433, 1982

    PubMed  Google Scholar 

  59. Frairia R, Agrimonti F, Barbadoro E, Fazzari A, Buccuzzi G, Angeli A: Evidence for a transcortin-like component in human breast cyst fluid. Clin Chim Acta 131:15–27, 1983

    PubMed  Google Scholar 

  60. Franchimont P, Dourcy C, Legros JJ, Reuter A, Vrindts-Gevaert Y, Van Cauwenberge JR, Remacle P, Gaspard U, Colin C: Dosage de la prolactine dans les conditions normales et pathologiques. Ann Endocrinol (Paris) 37:127–156, 1976

    Google Scholar 

  61. Franchimont P, Zangerle PF, Hendrick JC, Reuter A, Colin C: Simultaneous assays of cancer associated antigens in benign and malignant breast diseases. Cancer 39:2806–2812, 1977

    PubMed  Google Scholar 

  62. Franks S, Ralphs DNL, Seagroatt V, Jacobs HS: Prolactin concentration in patients with breast cancer. Brit Med J 4:320–321, 1974

    PubMed  Google Scholar 

  63. Frantz VK, Pickren JW, Melcher GW, Auchincloss H: Incidence of chronic cystic disease in so called ‘normal breasts’. A study based on 225 postmortem examinations. Cancer 4:762–783, 1951

    PubMed  Google Scholar 

  64. Friedman M, Finkler R, Antopol W: The relation of ovarian hormones to benign breast hyperplasia and neoplasia. Radiology 33:725–736, 1939

    Google Scholar 

  65. Funderburk WW, Rosero E, Lefall LD: Breast lesions in blacks. Surg Gynecol Obstet 135:58–60, 1972

    PubMed  Google Scholar 

  66. Gatzy JT, Zaytoun MP, Gaskins K, Pearlman WH: Electrolytes of breast-cyst fluid. Clin Chem 25:745–748, 1979

    PubMed  Google Scholar 

  67. Geller S, Grenier J, Nahoul K, Scholler R: Insuffisance luteale et mastopathies benignes. Etude a la lumier des donnees de l'epreuve combinee LH-RH + TRH couplee a l'etude des steroides ovariens. Ann Endocrinol (Paris) 40:45–46, 1979

    Google Scholar 

  68. Golinger RC, Krebs J, Fisher ER, Danowski TS: Hormones and the pathophysiology of fibrocystic mastopathy: Elevated luteinizing hormone levels. Surgery 84:212–215, 1978

    PubMed  Google Scholar 

  69. Gorlich M, Heise E, Pradja N, Hindy I: The excretion of 17-ketosteroids in patients suffering from mastopathia fibrocystica and mammary carcinomas. Arch Geschwulstforsch 45:648–657, 1975

    PubMed  Google Scholar 

  70. Grattarola R: The hormonal background of breast noncancerous diseases. Senologia 2:19–22, 1977

    Google Scholar 

  71. Grattarola R; Anovulation and increased androgenic activity at breast cancer risk in women with fibrocystic disease of the breast. Cancer Res 38:3051–3054, 1978

    PubMed  Google Scholar 

  72. Haagensen DE, Kister SJ, Vandevoorde JP, Gates JB, Smart EK, Hansen HJ, Wells SA: Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Cancer 42:1512–1519, 1978

    PubMed  Google Scholar 

  73. Haagensen CD: Disease of the Breast. WB Saunders, Philadelphia, 1971

    Google Scholar 

  74. Haagensen DE, Mazoujian G, Dilley WG, Pedersen CE, Kister SJ, Wells SA: Breast gross cystic disease fluid analysis. I. Isolation and radioimmunoassay for a major component protein. J Nat Cancer Inst 62:239–247, 1979

    PubMed  Google Scholar 

  75. Haagensen DE, Mazoujian G, Holder WD, Kister SJ, Wells SA: Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients. Ann Surg 185:279–285, 1977

    PubMed  Google Scholar 

  76. Hahnel R, Twaddle E, Vivian AB: Estrogen receptors in human breast cancer. 2. In vitro binding of estradiol by benign and malignant tumours. Steroids 18:681–708, 1971

    PubMed  Google Scholar 

  77. Hawkins RA, Hill A, Freedman B: A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues. Clin Chim Acta 64:203–210, 1975

    PubMed  Google Scholar 

  78. Hendrick JW: Results of treatment of carcinomas of breast; 5 to 18 years. Ann Surg 146:728–750, 1957

    PubMed  Google Scholar 

  79. Heyden S: Coffee and fibrocystic breast disease. Surgery 88:741–742, 1980

    PubMed  Google Scholar 

  80. Hilf R, Goldenberg H, Michel I, Orlando RA, Archer FL: Enzymes, nucleic acids, and lipids in human breast cancer and normal breast tissue. Cancer Res 30:1874–1882, 1970

    PubMed  Google Scholar 

  81. Hislop TG, Elwood JM, Risk factors for benign breast disease: A 30-year cohort study. Canadian Med Assoc J 124:283–291, 1981

    Google Scholar 

  82. Hodge J, Surver J, Aponte GG: Relationship of fibrocystic disease to carcinoma of breast: study based on 876 cases. AMA Arch Surg 79:670–678, 1959

    PubMed  Google Scholar 

  83. Hoff J, Hoff-Bardier M, Bayard F: La Prolactine: Son role dans l'hormonedependance des cancers du sein. J Gyn Obst Biol Reprod 7:19–30, 1978

    Google Scholar 

  84. Hsueh AJW, Peck EJ, Clark JH: Control of uterine oestrogen receptor level by progesterone. Endocrinology 98:438–444, 1976

    PubMed  Google Scholar 

  85. Hutchinson WB, Thomas DB, Hamlin WB, Roth GT, Peterson AV, Williams B: Risk of breast cancer in women with benign breast disease. J Nat Cancer Inst 65:13–20, 1980

    PubMed  Google Scholar 

  86. Janerich DT, Glebatis DM, Dugan JM: Benign breast disease and oral contraceptive use. J Am Med Ass 237: 2199–2201, 1977

    Google Scholar 

  87. Jenkins JS, Ash S: Metabolism of testosterone by human breast tumours. Lancet ii:513–514, 1972

    Google Scholar 

  88. Jones MK, Dyer GI, Ramsay ID, Collins WP: Studies on apparent free cortisol and testosterone in plasma from patients with breast tumours. Postgrad Med J 57:89–94, 1981

    Google Scholar 

  89. Jones MK, Ramsay ID, Collins WP: Concentration of testosterone glucuronide in urine from women with breast tumours. Brit J Cancer 35:885–887, 1977

    PubMed  Google Scholar 

  90. Jones MK, Ramsay ID, Collins WP: Plasma gonadotrophin concentrations in postmenopausal women with breast disease. Clin Oncol 5:305–309, 1979

    PubMed  Google Scholar 

  91. Kelsey JL, Holford TR, White C, Mayer ES, Kilty SE, Acheson RM: Oral contraceptives and breast disease. Am J Epidemiol 107:236–244, 1978

    PubMed  Google Scholar 

  92. Kelsey JL, Lindfors KK, White C: A case-control study of the epidemiology of benign breast diseases with reference to oral contraceptive use. Int J Epidemiol 3:333–340, 1974

    PubMed  Google Scholar 

  93. Kilgore AR, Fleming R, Ramos MM: The incidence of cancer with nipple discharge and the risk of cancer in the presence of papillary disease of the breast. Surg Gynec Obstet 96:649, 1973

    Google Scholar 

  94. Kodlin D, Winger EE, Morgenstern NL, Chen V: Chronic mastopathy and breast cancer. Cancer 39:2603–2607, 1977

    PubMed  Google Scholar 

  95. Koenig F: Mastitis chronica cystica. Zentralbl Chir 20:49–53, 1893

    Google Scholar 

  96. Korenman SG, Lipsett MB: Is testosterone glucuronoside uniquely derived from plasma testosterone? J Clin Invest 43:2125–2131, 1964

    PubMed  Google Scholar 

  97. Korenman SG, Lipsett MB: Direct peripheral conversion of dehydroepiandrosterone to testosterone glucuronoside. Steroids 5:509–517, 1965

    Google Scholar 

  98. Kramer WM, Rush BF: Mammary duct proliferation in the elderly. A histopathological study. Cancer 31:130–137, 1973

    PubMed  Google Scholar 

  99. Krompecher E: Zur Histogeneses und Morphologie de Cystenmamma. Beltr path Anat 62:403–472, 1916

    Google Scholar 

  100. Kumar S, Mansel RE, Scanlon MF, Hughes LE: Secretory response of prolactin and TSH in benign breast disease and after TRH stimulation. Brit J Surg 70:293, 1983

    Google Scholar 

  101. Kuttenn F, Fournier S, Durand JC, Mauvais-Jarvis P: Estradiol and progesterone receptors in human breast fibroadenomas. J Clin Endocrinol Metab 52:1225–1229, 1981

    PubMed  Google Scholar 

  102. Kuzmina ZV, Sharoukhova KS, Muravyova NI, Goncharova MG, Molodyk AA, Vyshnyakova VV: Some features in correlations of the ovarian cycle hormones in patients with mastopathy and mammary cancer. Vestn Akad Med Nauk 2:60–64, 1977

    Google Scholar 

  103. Latteri M, Bajardi G, Castiglione C, Caronia F, Maragliono S, Briganti A, Latteri S, Bellanca L: La prollatina nella patologia della mammella. Minerva Med 71:1915–1920, 1980

    PubMed  Google Scholar 

  104. Laurence DJR, Stevens U, Bettelheim R, Darcy D, Leese C, Turberville C, Alexander P, Johns EW, Neville AM: Role of plasma carcinoembryonic antigen in diagnosis of gastrointestinal, mammary and bronchial carcinoma. Brit Med J 3:605–609, 1972

    PubMed  Google Scholar 

  105. Lawson DH, Jick H, Rothman KJ: Coffee and tea consumption and breast disease. Surgery 90:801–803, 1981

    PubMed  Google Scholar 

  106. Leake R: Steroid receptors in normal and cancer tissue.In Stoll BA (ed): Hormonal Management of Endocrine-Related Cancer. Lloyd-Luke Ltd, London, 1981, pp 3–23

    Google Scholar 

  107. Leclercq G, Heuson JC, Deboel MC, Mattheiem WH: Oestrogen receptors in breast cancer: A changing concept. Brit Med J 1:185–189, 1975

    PubMed  Google Scholar 

  108. Lees AW, Burns PE, Grace M: Oral contraceptives and breast disease in premenopausal northern Albertan women. Int J Cancer 22:700–707, 1978

    PubMed  Google Scholar 

  109. Leung BS, Manaugh LC, Wood DC: Estradiol receptors in benign and malignant disease of the breast. Clin Chim Acta 46:69–76, 1973

    PubMed  Google Scholar 

  110. LiVolsi VA, Stadel BV, Kelsey JL, Holford TR, White C: Fibrocystic breast disease in oral contraceptive users. New Engl J Med 299:381–385, 1978

    PubMed  Google Scholar 

  111. Lloyd RV: Studies on the progesterone receptor content and steroid metabolism in normal and pathological human breast tissues. J Clin Endocrinol Metab 48: 585–593, 1979

    PubMed  Google Scholar 

  112. London RS, Sundaram GS, Schultz M, Nair PP, Goldstein PJ: Endocrine parameters and α-tocopherol therapy of patients with mammary dysplasia. Cancer Res 41:3811–3813, 1981

    PubMed  Google Scholar 

  113. Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR: Disordered nocturnal prolactin regulation in women with breast cancer. Cancer Res 37:4650–4654, 1977

    PubMed  Google Scholar 

  114. Manuilova IA, Pshenichnikova TY: Hypophysealovarian relationships in patients with diffuse fibrocystic mastopathy. Akush Ginekol 46:8–11, 1970

    Google Scholar 

  115. Marchesoni D, Gangemi M, Mozzanega B, Paternoster D, Graziottin A, Maggino T: Inadequate luteal phase and benign breast disease. Clin Exp Obstet Gynecol 8:160–163, 1981

    PubMed  Google Scholar 

  116. Marmoston J, Crowley LG, Myers SM, Stern E, Hopkins CE: 2. Urinary excretion of estrone, estradiol and estriol by patients with breast cancer and benign breast disease. Am J Obstet Gynecol 92:460–467, 1965

    PubMed  Google Scholar 

  117. Marmoston J, Crowley LG, Myers SM, Stern E, Hopkins CE: I. Urinary excretion of neutral 17-ketosteroids and pregnanediol of patients with breast cancer and benign breast disease. Am J Obstet Gynecol 92:447–459, 1965

    PubMed  Google Scholar 

  118. Martin PM, Kuttenn F, Serment H, Mauvais-Jarvis P: Studies on clinical, hormonal and pathological correlations in breast fibroadenomas. J Steroid Biochem 9:1251–1255, 1978

    PubMed  Google Scholar 

  119. Martin PM, Kuttenn F, Serment H, Mauvais-Jarvis P: Progesterone receptors in breast fibroadenomas. J Steroid Biochem 11:1295–1298, 1979

    PubMed  Google Scholar 

  120. Marx SJ, Zusman RM, Umiker WO: Benign breast dysplasia causing hypercalcemia. J Clin Endocrinol Metab 45:1049–1052, 1977

    PubMed  Google Scholar 

  121. Mauvais-Jarvis P, Sitruk-Ware R, Kuttenn F, Sterkers N: Luteal phase insufficiency: A common pathophysiologic factor in development of benign and malignant breast diseases. Commentaries on Research in Breast Diseases 1:25–29, 1979

    Google Scholar 

  122. Menendez-Botet CJ, Nisselbaum JS, Fleisher M, Rosen PP, Fracchia A, Robbins G, Urban JA, Schwartz MK: Correlation between estrogen receptor protein and carcinoembryonic antigen in normal and carcinomatous human breast tissue. Clin Chem 22:1366–1371, 1976

    PubMed  Google Scholar 

  123. Miller WR, Dixon JM, Scott WN, Forrest APM: Classification of human breast cysts according to electrolyte and androgen conjugate composition. Clin Oncol 9:227–232, 1983

    PubMed  Google Scholar 

  124. Miller WR, McDonald D, Forrest APM, Shivas AA: Metabolism of androgens by human breast tissue. Lancet i:912–913, 1973

    Google Scholar 

  125. Miller WR, Roberts MM, Creel RJ, Yap PL, Kelly RW, Forrest APM: Androgen conjugates in human breast cyst fluid. J Nat Cancer Inst 69:1055–1058, 1982

    PubMed  Google Scholar 

  126. Minton JP, Abou-Issa H, Reiches N, Roseman JM: Clinical and biochemical studies on methylxanthine-related fibrocystic breast disease. Surgery 90:299–303, 1981

    PubMed  Google Scholar 

  127. Minton JP, Foecking MK, Webster DJT, Matthews RH: Response of fibrocystic disease to caffeine withdrawal and correlation of cyclic nucleotide with breast disease. Am J Obstet Gynecol 135:157–158, 1979

    PubMed  Google Scholar 

  128. Minton JP, Foecking MK, Webster DJT, Matthews RH: Caffeine cyclic nucleotides and breast disease. Surgery 86:105–108, 1979

    PubMed  Google Scholar 

  129. Minton JP, Matthews RH, Wisenbaugh TW: Elevated levels of 3′5′-cyclic monophosphate levels in human and animal tumours in vivo. J Nat Cancer Inst 57:39–41, 1976

    PubMed  Google Scholar 

  130. Mirabile E, Zanghi M, Azzolina P: Esplorazione funzionale dell'asse diencefalo-anteipofisario e degli organi endocrini periferici notoriamente correlati all'attivita della mammella femminile, in casa clinici di mastopatia fibrocistica. Chirug Italiana 20:85–104, 1968

    Google Scholar 

  131. Monson RR, Yen S, Macmahon B, Warren S: Chronic mastitis and carcinoma of the breast. Lancet ii:224–226, 1976

    Google Scholar 

  132. Moore JW, Clark GMG, Bulbrook RD, Hayward JL, Murai JT, Hammond GL, Siiteri PK: Serum concentrations of total and non-protein-bound oestradiol in patients with breast cancer and in normal controls. Int J Cancer 29:17–21, 1982

    PubMed  Google Scholar 

  133. Moore SW, Pearce J, Ring E: Intraductal papilloma of the breast. Surg Gynecol Obstet 112:153–158, 1961

    Google Scholar 

  134. Morgan RW, Vakil DV, Chipman ML: Breast-feeding, family history and breast disease. Am J Epidemiol 99:117–122, 1974

    PubMed  Google Scholar 

  135. Mouravieva E, Manouylova IA, Smirnova N, Charooukhova K: Les particularites des desquilibres hormonaux dans la mastopathie. Acta Un Int Can 20:1124–1125, 1964

    Google Scholar 

  136. Nemoto T, Constantine R, Chu TM: Human tissue polypeptide antigen in breast cancer. J Nat Cancer Inst 63: 1347–1350, 1979

    PubMed  Google Scholar 

  137. Nomura A, Comstock GW: Benign breast tumor and estrogenic hormones: A population-based retrospective study. Am J Epidemiol 103:439–444, 1976

    PubMed  Google Scholar 

  138. Nomura A, Comstock GW, Tonascia JA: Epidemiologic characteristics of benign breast disease. Am J Epidemiol 105:505–512, 1977

    PubMed  Google Scholar 

  139. Ofuji N, Ogawa N, Miyoshi M, Takahara J, Ofuji T, Tanaka S, Itagaki F: Plasma prolactin and thyroid-stimulating hormone in patients with breast cancer. Folia Endocrinol Jap 52:595–571, 1976

    Google Scholar 

  140. Ohgo S, Kato Y, Chihara K, Imura H: Plasma prolactin responses to thyrotropin-releasing hormone in patients with breast cancer. Cancer 37:1412–1416, 1976

    PubMed  Google Scholar 

  141. Olsson H, Landin-Olsson M, Gullberg B: Retrospective assessment of menstrual cycle length in patients with breast cancer, in patients with benign breast disease and in women without breast disease. J Nat Cancer Inst 70:17–20, 1983

    PubMed  Google Scholar 

  142. Oluwole SF, Freeman HP: Analysis of benign breast lesions in blacks. Am J Surg 137:786–789, 1979

    PubMed  Google Scholar 

  143. Opri F, Kirchner H: Untersuchungen uber das carcinoembryonale Antigen (CEA) und uber die Enzymaktivitaten von alkalischer und saurer Phosphatase beim Mastopathia fibro-cystica. Zbl Gynakol 10:564–568, 1981

    Google Scholar 

  144. Opri F, Post G, Kirchner H, Hammerstein J: Bestimmung des HCG in Serum und in Zystenpunkten bei verscheidenen Formen der Mastopathik. Geburtsh und Frauenheilk 39:690–693, 1979

    Google Scholar 

  145. Ory H, Cole P, Macmahon B, Hoover R: Oral contraceptives and reduced risk of benign breast disease. New Engl J med 294:412–422, 1976

    Google Scholar 

  146. Ozieblo L: Serum prolactin levels in healthy women and in patients with functional disorders of the mammary glands. Endokrynol Pol 28:323–330, 1977

    PubMed  Google Scholar 

  147. Page DL, Vander Zwagg R, Rogers LW, Williams LT, Walker WE, Hartman WM: Relation between component parts of fibrocystic disease and breast cancer. J Nat Cancer Inst 61:1055–1063, 1978

    PubMed  Google Scholar 

  148. Papolczay A, Voros A, Bihari I: Chronic cystic mastopathya: Twenty-five years experience. Acta Chirurgica Acad Scientarum Hungaricae 19:349–356, 1978

    Google Scholar 

  149. Pastides H, Kelsey JL, Livolsi VA, Holford TR, Fischer DB, Goldenberg IS: Oral contraceptive use and fibrocystic disease with special reference to its histopathology. J Nat Cancer Inst 71:5–9, 1983

    PubMed  Google Scholar 

  150. Pearlman WH, Gueriguian JL, Sawyer ME; A specific progesterone-binding component of human breast cyst fluid. J Biol Chem 248:5736–5741, 1973

    PubMed  Google Scholar 

  151. Pearlman WH, Peng LH, Mazoujian G, Haagensen DE, Wells SA, Kister SJ: A specific progesterone-binding component of human breast cyst fluid: its isolation and characterization. J Endocrinol 75:19P-20P, 1977

    PubMed  Google Scholar 

  152. Pearson OH, Llerena O, Llerena L, Molina A, Butler T: Prolactin-dependent rat mammary cancer: A model for man? Trans Assoc Am Physicians 82:225–237, 1969

    PubMed  Google Scholar 

  153. Pfaffenberger CD, Malinak LR, Horning EC: Study of urinary steroid metabolite ratios of women with breast lesions using open-tubular glass capillary columns. J Chromatog 158:313–330, 1978

    Google Scholar 

  154. Potter JP, Slimbaugh WP, Woodward SC: Can breast carcinoma be anticipated? A follow-up of benign breast biopsies. Ann Surg 167:829–838, 1968

    PubMed  Google Scholar 

  155. Raju U, Ganguly M, Levitz M: Estriol conjugates in human breast cyst fluid and in serum of premenopausal women. J Clin Endocrinol Metab 45:429–434, 1977

    PubMed  Google Scholar 

  156. Ravnihar B, Seigel DG, Lindtner J: An epidemiologic study of breast cancer and benign breast neoplasias in relation to the oral contraceptive and estrogen use. Europ J Cancer 15:395–405, 1979

    Google Scholar 

  157. Reed MJ, Cheng RW, Noel CT, Dudley HAF, James VHT: Plasma levels of estrone, estrone sulfate and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res 43:3940–3943, 1983

    PubMed  Google Scholar 

  158. Rolland PH, Martin PM, Bourry M, Rolland AM, Serment H: Human benign breast disease: Relationships between prostaglandin E2, steroid hormones and thermographic effects of the inhibitors of prostaglandin biosynthesis. Adv Prostaglandin Thromboxane Res 6:581–584, 1980

    PubMed  Google Scholar 

  159. Rolland PH, Martin PM, Bourry M, Serment H: Prostaglandines et mastopathie benigne. J Gyn Obst Biol Repr 10:197–201, 1981

    Google Scholar 

  160. Rolland PH, Martin PM, Rolland AM, Bourry M, Serment H: Benign breast disease: Studies of prostaglandin E2, steroids and thermographic effects of inhibitors of prostaglandin biosynthesis. Obstet Gynecol 54:715–718, 1979

    PubMed  Google Scholar 

  161. Rose LI, Underwood RH, Dunning MT, Williams GH, Pinkus GS: Testosterone metabolism in benign and malignant breast lesions. Cancer 36:399–403, 1975

    PubMed  Google Scholar 

  162. Rosen PP, Menendez-Botet CJ, Nisselbaum JS, Urban JA, Mike V, Fracchia A, Schwartz MK: Pathological review of breast lesions analyzed for estrogen receptor protein. Cancer Res 35:3187–3194, 1975

    PubMed  Google Scholar 

  163. Royal College of General Practitioners: Effect on hypertension and benign breast disease of progestagen component in combined oral contraceptives. Lancet i:624, 1977

    Google Scholar 

  164. Sartwell PE, Arthes FG, Tonascia JA: Epidemiology of benign breast lesions: Lack of associations with oral contraceptive use. New Engl J Med 288:551–554, 1973

    PubMed  Google Scholar 

  165. Sartwell PE, Arthes FG, Tonascia JA: Benign and malignant breast tumours: Epidemiological similarities. Int J Epidemiol 7:217–221, 1978

    PubMed  Google Scholar 

  166. Sasano N, Tateno H, Stemmermann GN: Volume and hyperplastic lesions of breasts of Japanese women in Hawaii and Japan. Prev Med 7:196–204, 1978

    PubMed  Google Scholar 

  167. Sasse F: Uber Cysten und cystische Turnoven der Mamma. Arch Klin Chir 54:1–54, 1897

    Google Scholar 

  168. Schimmelbusch C: Das Cystadenom der Mamma. Arch Klin Chir 44:117–134, 1892

    Google Scholar 

  169. Schubert K, Bacigalupo G: Steroidstoffwechsel bei Mastapathie unter Ostradioleinwirkung. Arch Geschwulstforsch 61:207–217, 1960

    Google Scholar 

  170. Schuerch C, Rosen PP, Hirota T, Itabashi M, Yamamoto H, Kinne DW, Beattie EJ: A pathologic study of benign breast diseases in Tokyo and New York. Cancer 50:1899–1903, 1982

    PubMed  Google Scholar 

  171. Schwartz MK, Fleisher M, Breed C, Ashikari R, DePalo A, Kinne D, Urban J: Enzyme composition of human breast cyst fluid. Clin Chem 22:1213, 1976

    Google Scholar 

  172. Secreto G, Fariselli G, Bandieramonte G, Recchione C, Dati V, DiPietro S: Androgen excretion in women with a family history of breast cancer or with epithelial hyperplasia or cancer of the breast. Europ J Cancer Clin Oncol 19:5–10, 1983

    PubMed  Google Scholar 

  173. Semb C: Pathologico-anatomical and clinical investigations of fibroadenomatosis cystea mammae and its relationship to other pathological conditions. Acta Chir Scandinavia 64 Suppl 10:1–484, 1928

    Google Scholar 

  174. Serban MD, Stroe E, Klepsch I, Busila E, Garoiu M: Data hormonale in mastopatii. Studii cercetari endocr 14:399–408, 1963

    Google Scholar 

  175. Sherman BM, Korenman SG: Inadequate corpus luteum function: A pathophysiological interpretation of human breast cancer epidemiology. Cancer 33:1306–1312, 1974

    PubMed  Google Scholar 

  176. Sheth NA, Ranadive KJ, Suraiya JN, Sheth AR: Circulating levels of prolactin in human breast cancer. Brit J Cancer 32:160–167, 1975

    PubMed  Google Scholar 

  177. Shousha S, Lyssiotis T: Correlation of carcinoembryonic antigen in tissue sections with spread of mammary carcinoma. Histopathol 2:433–447, 1978

    Google Scholar 

  178. Silverberg SG, Chitale AR, Levitt SH: Prognostic implications of fibrocystic dysplasia in breasts removed for mammary carcinoma. Cancer 29:574–580, 1972

    PubMed  Google Scholar 

  179. Simkin B: Elevated serum prolactin in women with benign and malignant breast disease. 64th Annual meeting of the U.S. Endocrine Society, p 443, 1982

  180. Singhakowinta A, Mohindra R, Brooks SC, Vaitkevicius VK, Brennan MJ: Clinical correlation of endocrine therapy and estrogen receptor.In McGuire WH, Carbone PP, Vollmer EP (eds): Estrogen Receptors in Human Breast Cancer. Raven Press, New York, pp. 131–148, 1975

    Google Scholar 

  181. Sitruk-Ware LR, Sterkers N, Mowszowicz I, Mauvais-Jarvis P: Inadequate corpus luteum function in women with benign breast disease. J Clin Endocrinol Metab 44:771–774, 1977

    PubMed  Google Scholar 

  182. Soini I, Aine R, Lauslahti K, Hakama M: Independent risk factors of benign and malignant breast lesions. Am J Epidemiol 114:507–514, 1981

    PubMed  Google Scholar 

  183. Srivastava LS, Pescovitz H, Singh RD, Perisutti G, Knowles HC: Radioimmunoassay of some hormones simultaneously measured in serum and breast cyst fluid. Experientia 33:1659–1660, 1977

    PubMed  Google Scholar 

  184. Steward AM, Nixon D, Zamcheck N, Aisenberg A: Carcinoembryonic antigen in breast cancer patients: Serum levels and disease progress. Cancer 33:1246–1252, 1974

    PubMed  Google Scholar 

  185. Sundaram GS, London R, Margolis S, Wenk R, Lustgarten J, Nair PP, Goldstein P: Serum hormones and lipoproteins in benign breast disease. Cancer Res 41: 3814–3816, 1981

    PubMed  Google Scholar 

  186. Swain MC, Hayward JL, Bulbrook RD: Plasma oestradiol and progesterone in benign breast disease. Europ J Cancer 9:553–556, 1973

    Google Scholar 

  187. Tarquini A, Di Martino L, Malloci A, Kwa HG, Van Der Gugten AA, Bulbrook RD, Wang DY: Abnormalities in evening plasma prolactin levels in nulliparous women with benign or malignant breast disease. Int J Cancer 22:687–690, 1978

    PubMed  Google Scholar 

  188. Tarquini B, Gheri R, Romano S, Costa A, Cagnoni M, Lee JK, Halberg F: Circadian variation of serum prolactin and TSH of women in health or with mammary carcinoma, fibroadenoma or fibrocystic mastopathy. Int J Chronobiology 7:101–115, 1980

    Google Scholar 

  189. Taylor-Papadimitriou J, Purkis P, Fentiman IS: Cholera toxin and analogues of cyclic AMP stimulate the growth of cultured human mammary epithelial cells. J Cell Physiol 102:317–321, 1980

    PubMed  Google Scholar 

  190. Terenius L, Johansson H, Rimsten A, Thoren L: Malignant and benign human mammary disease: Estrogen binding in relation to clinical data. Cancer 33:1364–1368, 1974

    PubMed  Google Scholar 

  191. Thomas DB: Role of exogenous female hormones in altering the risk of benign and malignant neoplasms in humans. Cancer Res 38:3991–4000, 1978

    PubMed  Google Scholar 

  192. Thomas DB, Persing JP, Hutchinson WB: Exogenous estrogens and other risk factors for breast cancer in women with benign breast disease. J Nat Cancer Inst 69:1017–1025, 1982

    PubMed  Google Scholar 

  193. Thynne GSJ, Greening WP: A correlation of erythrocyte sedimentation and plasma carcinoembryonic antigen in fibrocystic disease and carcinoma of the breast. Clin Oncol 6:317–321, 1980

    PubMed  Google Scholar 

  194. Tseng L, Gusberg SB, Gurpide E: Estradiol receptor and 17β-dehydrogenase in normal and abnormal human endometrium. Ann NY Acad Sci 286:190–198, 1977

    PubMed  Google Scholar 

  195. Varnavides LN, O'Higgins NJ, Clark CG: Carcinoembryonic antigen (CEA) in mammary disease: a clinical evaluation. Clin Oncol 4:329–337, 1978

    PubMed  Google Scholar 

  196. Veronesi V, Pizzocaro G: Breast cancer in women subsequent to cystic disease of the breast. Surg Gynecol Obstet 126:529–532, 1968

    PubMed  Google Scholar 

  197. Vessey MP, Doll R, Sutton PM: Oral contraceptives and breast neoplasia: A retrospective study. Brit Med J 3:719–724, 1972

    PubMed  Google Scholar 

  198. Walsh PV, Wang DY, McDicken I, Stell PM, Bulbrook RD, George D: Serum progesterone concentration during the luteal phase in women with benign breast disease. Europ J Cancer Clin Oncol 20:1339–1343, 1984

    PubMed  Google Scholar 

  199. Wang DY: Secretion and metabolism of hormones by tumours.In Stoll BA (ed): Hormonal Management of Endocrine-Related Cancer. Lloyd-Luke Ltd, London, pp 30–40, 1981

    Google Scholar 

  200. Wang DY: Steroid metabolism and ectopic hormone production in breast cancer.In Stoll BA (ed): Endocrine Relationships in Breast Cancer. Heinemann, London, pp 68–84, 1982

    Google Scholar 

  201. Wang DY, Hayward JL, Bulbrook RD: Testosterone levels in the plasma of normal women and patients with benign breast disease or breast cancer. Europ J Cancer 2:373–376, 1966

    Google Scholar 

  202. Wang DY, Bulbrook RD: Hormones and neoplasia.In Raven RW (ed): Principles of Surgical Oncology. Plenum, New York, pp. 227–261, 1977

    Google Scholar 

  203. Wang DY, Knyba RE, Bulbrook RD, Millis RR, Hayward JL: Serum carcinoembryonic antigen in diagnosis and prognosis of women with breast cancer. Europ J Cancer Clin Oncol 20:25–31, 1984

    PubMed  Google Scholar 

  204. Wang DY, Sturzaker HE, Kwa HG, Verhofstad F, Hayward JL, Bulbrook RD: Nycthemeral changes in plasma prolactin levels and its relationship to breast cancer risk. Int J Cancer 33:629–632, 1984

    PubMed  Google Scholar 

  205. Warren JC: The surgeon and the pathologist. A plea for reciprocity as illustrated by the considerations of the classification and treatment of benign tumours of the breast. JAMA 45:149–165, 1905

    Google Scholar 

  206. Watt-Boolsen S, Emus HC, Junge J: Fibrocystic disease and mastalgia: A histological and enzyme-histochemical study. Danish Med Bull 29:252–254, 1982

    PubMed  Google Scholar 

  207. Wellings SR, Jensen HM, Marcum RG: An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Nat Cancer Inst 55:231–273, 1975

    PubMed  Google Scholar 

  208. Wilkinson EJ, Hause LL, Sasse EA, Pattillo RA, Millbrath JR, Lewis JD: Carcinoembryonic antigen and L-fucose in malignant and benign mammary disease. Am J Clin Path 73:669–675, 1980

    PubMed  Google Scholar 

  209. Witkin SS, Richards JM, Bongiovanni AM, Breed CN, Day NK: Sera from breast cancer patients contain an IgA antibody to a breast cyst fluid component. Clin Immunol Immunopath 23:358–365, 1982

    Google Scholar 

  210. Witkin SS, Sarkar NH, Kinne DW, Breed CN, Good RA, Day NK: Antigens and antibodies cross-reactive to the murine mammary tumour virus in human breast cyst fluids. J Clin Invest 67:216–222, 1981

    PubMed  Google Scholar 

  211. Wittekind C, Von Kleist S, Sandritter W: CEA positivity in tissue and sera of patients with benign breast lesions. Oncodev Biol Med 2:381–390, 1981

    PubMed  Google Scholar 

  212. Wurster K, Heberling D, Rapp W: CEA und Laktoferrin bei gutartigen und bosartigen Erkrankungen der Mamma. Geburtsh Frauenheilk 40:412–422, 1980

    PubMed  Google Scholar 

  213. Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. New Engl J Med 312:146–151, 1985

    PubMed  Google Scholar 

  214. Boyle CA, Berkowitz GS, LiVolsi VA, Ort S, Merino MJ, White C, Kelsey JL: Caffeine consumption and fibrocystic disease: A case-control epidemiological study. J Nat Cancer Inst 72:1015–1019, 1984

    PubMed  Google Scholar 

  215. Kumar S, Mansel RE, Hughes LE, Woodhead JS, Edwards CA, Scanlon MF, Newcombe RG: Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease. Cancer 53:1311–1315, 1984

    PubMed  Google Scholar 

  216. Peters F, Schuth W, Scheurich B, Breckwoldt M: Serum prolactin levels in patients with fibrocystic breast disease. Obstet Gynecol 64:381–385, 1984

    PubMed  Google Scholar 

  217. Van Luchene E, Van de Kerckhove D, De Boever J, Sandra P: Structures and concentrations of fifteen different steroid sulfates in human breast cyst fluid. J Steroid Biochem 21:367–371, 1984.

    PubMed  Google Scholar 

  218. Yap PL, Miller WR, Roberts MM, Creel RJ, Freedman B, Mirtle CL, Pryde EAD, McClelland DBL: Protein concentrations in fluid from gross cystic disease of the breast. Clin Oncol 10:35–43, 1984

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Clinical Endocrinology, Imperial Cancer Research Fund, Lincoln's Inn Fields, WC2A 3PX, London, England

    D. Y. Wang

  2. Breast Unit, Guy's Hospital, SE1 9RT, London, England

    I. S. Fentiman MD (FRCS)

Authors
  1. D. Y. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. S. Fentiman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, D.Y., Fentiman, I.S. Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Tr 6, 5–36 (1985). https://doi.org/10.1007/BF01806008

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806008

Keywords

Search

Navigation